Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-29
DOI
10.1007/s11523-019-00632-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
- (2019) Iosune Baraibar et al. DRUG SAFETY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
- (2019) Maddalena Centanni et al. CLINICAL PHARMACOKINETICS
- Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
- (2019) Huan-huan Ji et al. CLINICAL DRUG INVESTIGATION
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
- (2018) Ariane G. S. Araujo et al. BIODRUGS
- Immune-mediated cholangitis: is it always nivolumab’s fault?
- (2018) Francesco Gelsomino et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
- (2018) Daniel L. Suzman et al. LIVER INTERNATIONAL
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
- (2018) Jeffrey M. Clarke et al. Targeted Oncology
- Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries
- (2018) Marion Ferreira et al. Targeted Oncology
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
- (2018) Yasuo Oshima et al. JAMA Oncology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Anti-Programmed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis
- (2018) Kohei Ogawa et al. HEPATOLOGY
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab
- (2018) Shoko Noda-Narita et al. EUROPEAN JOURNAL OF CANCER
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA
- (2018) Chisato Fukazawa et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
- (2018) Cheng Xu et al. BMJ-British Medical Journal
- Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology
- (2017) R.E. Kibbelaar et al. EUROPEAN JOURNAL OF CANCER
- Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements
- (2017) Herbert L. Bonkovsky et al. HEPATOLOGY
- ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
- (2017) Emanuel Raschi et al. Internal and Emergency Medicine
- Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data
- (2017) Wenjun Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
- (2017) Hisato Kawakami et al. INVESTIGATIONAL NEW DRUGS
- A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
- (2017) Francesco Gelsomino et al. INVESTIGATIONAL NEW DRUGS
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies
- (2017) Ayad K. Ali et al. PHARMACOTHERAPY
- Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
- (2017) Amandine Gouverneur et al. Targeted Oncology
- Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs
- (2017) Ankur Arora et al. Therapeutics and Clinical Risk Management
- The value of patient reporting to the pharmacovigilance system: a systematic review
- (2016) Pedro Inácio et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immuno-Oncology: The Third Paradigm in Early Drug Development
- (2016) Juan Martin-Liberal et al. Targeted Oncology
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites
- (2015) Kristina Juhlin et al. DRUG SAFETY
- An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
- (2015) Miguel-Angel Maciá-Martínez et al. DRUG SAFETY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database
- (2014) Paola M. Cutroneo et al. DRUG SAFETY
- Adverse reactions to oncologic drugs: spontaneous reporting and signal detection
- (2014) Marco Tuccori et al. Expert Review of Clinical Pharmacology
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Choosing Thresholds for Statistical Signal Detection with the Proportional Reporting Ratio
- (2013) Jim Slattery et al. DRUG SAFETY
- Data Mining of the Public Version of the FDA Adverse Event Reporting System
- (2013) Toshiyuki Sakaeda et al. International Journal of Medical Sciences
- The Global Evidence Mapping Initiative: Scoping research in broad topic areas
- (2011) Peter Bragge et al. BMC Medical Research Methodology
- Mapping the Safety Profile of Biologicals
- (2010) Thijs J. Giezen et al. DRUG SAFETY
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now